4 completed, 1 not yet recruiting, 1 withdrawn. 3 Phase 2, 2 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Early Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Nevus, Sebaceous of Jadassohn: new trials by email Literature Review of Nevus, Sebaceous of Jadassohn trials Research Report on Nevus, Sebaceous of Jadassohn
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pilot Study to Examine the Efficacy and Tolerability of Sirolimus on Epidermal Nevi Lesions in Patients 6 Years Old and Above. sirolimus topical gel 0.2% - Epidermal Nevi | Early Phase 1 | Not yet recruiting | Northwestern University | 14 | 2026-10-01 | 2026-09-10 |
| 12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi NFX-179 Gel 1.50% - Epidermal Nevi, Nevus Sebaceus | Phase 2 | Withdrawn | Albert Chiou | 2023-06-01 | 2024-05-28 | |
| A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS) Crysvita (burosumab-twza) Treatment - Epidermal Nevus Syndrome | Phase 4 | Completed | University of Alabama at Birmingham | 1 | 2020-07-31 | 2022-10-07 |
| Burosumab for CSHS Burosumab - Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome | Early Phase 1 | Completed | Laura Tosi | 1 | 2019-07-01 | 2026-07-30 |
| A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome KRN23 - Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 14 | 2016-04-01 | 2022-09-06 |
| Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) Burosumab - Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS) | Phase 2 | Completed | Kyowa Kirin, Inc. | 17 | 2015-03-24 | 2024-05-06 |
Abnormalities, Multiple (6) · Congenital Abnormalities (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Nervous System Diseases (6) · Neurocutaneous Syndromes (6) · Nevi and Melanomas (6) · Nevus (6)
burosumab (4) · Therapeutics (1)
Albert Chiou (1) · Kyowa Kirin Co., Ltd. (1) · Kyowa Kirin, Inc. (1) · Laura Tosi (1) · Northwestern University (1) · University of Alabama at Birmingham (1)
United States (5) · Japan (1) · South Korea (1)
Albert S Chiou, MD, MBA (1) · Amy Paller, MD (1) · Hussein Abdul-Latif, MD (1) · Laura Tosi, MD (1)